Country Reports

The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US healthcare industry during one of its most defining periods, look at how far the…

See Full Report

Puerto Rico has a stronger healthcare manufacturing footprint than any other US jurisdiction or State, with 50 pharma and 30 medical device sites dotted throughout the island. This footprint represents around 30 percent of Puerto Rico’s GDP and two of its major exports. Several multinational firms are doubling down on their commitment to manufacturing on…

See Full Report

With a fresh, business-minded administration in place, economic growth, a burgeoning middle class, and a greater openness towards cooperation between the public and private sectors, the fundamentals are there for Ecuador’s life sciences industry to shine. Medicine sales per capita are extremely high for Latin America and the dollarization of the economy is helping soothe…

See Full Report

With an exit from a period of recession in 2017, a new era of change and positivity is underway in Brazil. Stakeholders from across the public and private sectors are pulling together through strategic partnerships and dialogues to increase both the quantity and quality of the healthcare provided to the 160 million Brazilians who rely…

See Full Report

With economic prosperity, political stability and significant growth prospects, Canada has much to admire. However, Canadians still lack universal drug coverage and Canadian health innovation has lagged behind that of the world leaders in this area.   This report explores how these discrepancies are being remedied; including state R&D investment initiatives, increased inter-stakeholder dialogue, and…

See Full Report

With steady GDP growth, political stability and the best healthcare system in Latin America, Colombia’s life sciences industry has all the ingredients for success laid out before it. Indeed, with the domestic pharmaceutical market set to grow at a rate of around 7.3 percent and reach a USD 7.1 billion valuation by 2020, coupled with…

See Full Report

Meanwhile the country’s newly appointed minister of health has been audacious in radically reshuffling the rules of the game to place public healthcare provision “firmly on a pathway to sustainability.” “A corner has been turned and we are well on the way to establishing the enabling environment for an enduring healthcare system that is viable…

See Full Report

The report offers companies, investors, policymakers, and stakeholders with an interest in healthcare, pharmaceuticals, or life sciences insights into the fifth largest territory in the world for pharma manufacturing, a territory with significantly improved capabilities in R&D, medical device and diagnostics manufacturing, and more universities per square mile than anywhere else on the planet. It…

See Full Report

Meanwhile the country’s newly appointed minister of health has been audacious in radically reshuffling the rules of the game to place public healthcare provision “firmly on a pathway to sustainability.” “A corner has been turned and we are well on the way to establishing the enabling environment for an enduring healthcare system that is viable…

See Full Report
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here